 |
市場調查報告書
商品編碼
1767679
Herceptin市場按類型、應用、分銷管道、付款人類型、給藥途徑、治療線、患者屬性和地區分類Herceptin Market, By Type, By Application, By Distribution Channel, By Payer Type, By Administration Route, By Treatment Line, By Patient Demographics, By Geography |
||||||
價格
簡介目錄
Herceptin市場規模預計在 2025 年為 33 億美元，預計到 2032 年將達到 48.4 億美元，2025 年至 2032 年的複合年成長率為 5.62%。
| 分析範圍 | 分析詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 市場規模（2025年） | 33億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2025-2032 |
| 預測期內的複合年成長率（2025-2032） | 5.62% | 預計金額（2032年） | 48.4億美元 |
近年來，受 HER2 陽性乳癌發病率上升及標靶治療需求成長的推動，全球Herceptin市場經歷了顯著成長。Herceptin，又稱曲妥珠單抗，是一種特異性針對 HER2 蛋白的單株抗體，該蛋白在約 20-30% 的乳癌中過度表現。
該藥物徹底改變了 HER2 陽性乳癌的治療模式，改善了患者的預後和存活率。Herceptin的適應症不斷擴大，包括其用於治療 HER2 陽性轉移性胃癌，進一步推動了市場的成長。此外，生物相似藥的開發以及Herceptin與其他治療方法聯合使用的日益普及，為市場成長開闢了新的途徑。本報告對全球Herceptin市場進行了詳細分析，重點介紹了市場促進因素、限制因素、機會和未來前景。
市場動態：
全球Herceptin市場受到多種因素驅動，包括 HER2 陽性乳癌發病率的上升、標靶治療意識的增強以及個人化醫療需求的不斷成長。 HER2 表達伴隨診斷測試的發展也促進了市場成長，因為它能夠識別出最能從Herceptin治療中受益的患者。 然而，Herceptin治療的高成本可能會限制其在某些地區的普及，從而抑制市場成長。 此外，生物相似藥的出現和Herceptin在某些國家的專利到期到期也可能影響原廠藥的市場佔有率。 儘管有這些挑戰，市場提供了巨大的成長機會，包括Herceptin適應症擴展到其他 HER2 陽性癌症、開發新型藥物組合以及Herceptin在新興經濟體中的日益普及。 此外，旨在提高Herceptin療效和安全性的持續研發預計將在未來推動市場成長。
本報告的主要特點
- 本報告對全球Herceptin市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和復合年成長率。
- 它還強調了每個細分市場的潛在商機，並解釋了該市場的有吸引力的投資提案矩陣。
- 它還提供了有關市場促進因素、限制因素和機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
- 全球Herceptin市場的主要企業是根據公司概況、產品系列、主要亮點、財務績效和策略等參數進行分析的。
- 透過本報告的見解，負責人和企業經營團隊可以就未來的產品發布、合作夥伴關係、市場擴張和行銷策略做出明智的決策。
- 「全球Herceptin市場」報告涉及該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過用於分析全球Herceptin市場的各種策略矩陣來促進他們的決策。
目錄
第1章 分析目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
第3章市場動態、法規與趨勢分析
- 市場動態
- 驅動程式
- 限制因素
- 機會
- 影響分析
- 主要進展
- 監管情景
- 產品發布/核准
- PEST分析
- 波特五力分析
- 企業合併（M&A）場景
- 產業趨勢
第4章 全球Herceptin市場（依類型）（2020-2032）
- 生技藥品
- 生物相似藥
5. 全球Herceptin市場應用（2020-2032）
- 乳癌治療
- 胃癌治療
6. 全球Herceptin市場依通路分類（2020-2032 年）
- 醫院藥房
- 零售藥局
- 網路藥局
7. 全球Herceptin市場按付款人類型分類（2020-2032）
- 公共
- 私人的
8. 全球Herceptin市場依給藥途徑分類（2020-2032 年）
- 靜脈
- 皮下
9. 全球Herceptin市場按治療線分類（2020-2032 年）
- 一線治療
- 二線治療
- 三線治療
第 10 章 全球Herceptin市場（依病患人口統計） （2020-2032 年）
- 年齡層
第 11 章 按地區分類的全球Herceptin市場（2020-2032 年）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東地區
- 非洲
- 南非
- 北非
- 中部非洲
第12章競爭格局
- Genentech（Roche）
- Amgen
- Pfizer
- Merck & Co.
- AbbVie
- Celgene
- Bristol-Myers Squibb
- AstraZeneca
- GSK（GlaxoSmithKline）
- Novartis
- Sanofi
- Teva Pharmaceuticals
- Regeneron Pharmaceuticals
- Takeda Pharmaceutical Company
- EMD Serono
第13章 分析師建議
- “命運之輪”
- 分析師觀點
- Coherent Opportunity Map (COM)
第14章參考文獻與調查方法
- 參考
- 分析方法
- 關於 Coherent Market Insights
簡介目錄
Product Code: CMI8076
Herceptin Market is estimated to be valued at USD 3.30 Bn in 2025 and is expected to reach USD 4.84 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.62% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 3.30 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.62% | 2032 Value Projection: | USD 4.84 Bn |
The global Herceptin market has witnessed significant growth in recent years, driven by the increasing prevalence of HER2-positive breast cancer and the rising demand for targeted therapies. Herceptin, also known as trastuzumab, is a monoclonal antibody that specifically targets the HER2 protein, which is overexpressed in approximately 20-30% of breast cancers.
The drug has revolutionized the treatment landscape for HER2-positive breast cancer, improving patient outcomes and survival rates. The market's growth is further fueled by the expanding indications of Herceptin, including its use in the treatment of HER2-positive metastatic gastric cancer. Moreover, the development of biosimilars and the increasing adoption of Herceptin in combination with other therapies have opened up new avenues for market growth. This report provides an in-depth analysis of the global Herceptin market, highlighting its key drivers, restraints, opportunities, and future prospects.
Market Dynamics:
The global Herceptin market is driven by several factors, including the rising incidence of HER2-positive breast cancer, increasing awareness about targeted therapies, and the growing demand for personalized medicine. The development of companion diagnostic tests for HER2 expression has also contributed to the market's growth by enabling the identification of patients who are most likely to benefit from Herceptin treatment. However, the market growth is restrained by the high cost of Herceptin therapy, which may limit its accessibility in certain regions. Additionally, the emergence of biosimilars and the expiration of patents for Herceptin in some countries may impact the market share of the original drug. Despite these challenges, the market presents significant opportunities for growth, such as the expanding indications of Herceptin in other HER2-positive cancers, the development of novel drug combinations, and the increasing adoption of Herceptin in emerging economies. Furthermore, the ongoing research and development activities aimed at improving the efficacy and safety of Herceptin are expected to drive market growth in the coming years.
Key Features of the Study:
- This report provides in-depth analysis of the global Herceptin market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Herceptin market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Genentech (Roche), Amgen, Pfizer, Merck & Co., AbbVie, Celgene, Bristol-Myers Squibb, AstraZeneca, GSK (GlaxoSmithKline), Novartis, Sanofi, Teva Pharmaceuticals, Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, and EMD Serono
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Herceptin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Herceptin market
Market Segmentation
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Biologic
- Biosimilars
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Breast Cancer Treatment
- Gastric Cancer Treatment
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Payer Type Insights (Revenue, USD Bn, 2020 - 2032)
- Public
- Private
- Administration Route Insights (Revenue, USD Bn, 2020 - 2032)
- Intravenous
- Subcutaneous
- Treatment Line Insights (Revenue, USD Bn, 2020 - 2032)
- First-line Treatment
- Second-line Treatment
- Third-line Treatment
- Patient Demographics Insights (Revenue, USD Bn, 2020 - 2032)
- Age Groups
- Pediatric
- Adult
- Geriatric
- Gender
- Male
- Female
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Genentech (Roche)
- Amgen
- Pfizer
- Merck & Co.
- AbbVie
- Celgene
- Bristol-Myers Squibb
- AstraZeneca
- GSK (GlaxoSmithKline)
- Novartis
- Sanofi
- Teva Pharmaceuticals
- Regeneron Pharmaceuticals
- Takeda Pharmaceutical Company
- EMD Serono
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Herceptin Market, By Type
- Global Herceptin Market, By Application
- Global Herceptin Market, By Distribution Channel
- Global Herceptin Market, By Payer Type
- Global Herceptin Market, By Administration Route
- Global Herceptin Market, By Treatment Line
- Global Herceptin Market, By Patient Demographics
- Global Herceptin Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Herceptin Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Biologic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Biosimilars
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Herceptin Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Breast Cancer Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gastric Cancer Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Herceptin Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Herceptin Market, By Payer Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Herceptin Market, By Administration Route, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Herceptin Market, By Treatment Line, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- First-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Second-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Third-line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Herceptin Market, By Patient Demographics, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Age Groups
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pediatric
- Adult
- Geriatric
- Gender
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Male
- Female
11. Global Herceptin Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Payer Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Administration Route, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Treatment Line, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Patient Demographics, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Genentech (Roche)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celgene
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GSK (GlaxoSmithKline)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- EMD Serono
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
